Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (6.500.000 €): Vorhersage des Einflusses von monoklonalen Antikörpern und Impfstoffen auf antimikrobielle Resistenzen Hor01.11.2021 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Vorhersage des Einflusses von monoklonalen Antikörpern und Impfstoffen auf antimikrobielle Resistenzen
Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-species transfer of genetic mobile elements harbouring resistance genes, global transport and environmental waste. With an almost empty antibiotic pipeline, monoclonal antibodies (mAbs) and vaccines are increasingly recognized as important tools against AMR. Yet, available resources cannot finance all potential interventions, and choices need to be made according to costs of mAbs and vaccines, impact on the burden of AMR and prevention of its economic consequences. The PrIMAVeRa consortium will develop a web-based platform that combines advanced mathematical models with a comprehensive epidemiological repository. Systematic reviews will generate data to inform the model structure and parametrisation and select the most appropriate models for determining the AMR burden by pathogen, infection and target population. Deterministic continuous time models (ordinary differential equations [ODE]) and stochastic discrete time individual-based models with multiple modules will cover all relevant aspects of AMR, while Bayesian approaches will be used for cost-effectiveness analysis. The models will be calibrated in 8 EU countries based on the data coming from health information systems. The PrIMAVeRa consortium comprises a prominent collection of European research groups with expertise in AMR, vaccines, mAbs, mathematical and economical modelling. The proposal builds on established research collaborations and existing research infrastructures from EU- and IMI-funded research projects, such as EPI-Net (COMBACTE-MAGNET) and CLIN-Net and LAB-Net (COMBACTE-NET). The major deliverable will be an open access web-based user interface that will allow the wider scientific community to freely access and apply the models. This platform will also help healthcare authorities to make data-driven decisions on which vaccines and mAbs should be prioritised.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Ares Genetics GmbH | 129.275 € |
| Danmarks Tekniske Universitet | 478.275 € |
| 546.275 € | |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 76.275 € |
| EUROPEAN VACCINE INITIATIVE e. V. | 1.120.600 € |
| Glaxosmithkline Biologicals SA | 0,00 € |
| Institut Pasteur | 396.275 € |
| 660.550 € | |
| Janssen Vaccines & Prevention B.V. | 0,00 € |
| LIFE SCIENCE NETWORK gGmbH | 114.275 € |
| 139.275 € | |
| Pfizer Ltd. | 0,00 € |
| 292.275 € | |
| 6.000,00 € | |
| The Chancellor, Masters and Scholars of the University of Oxford | 321.275 € |
| UNIVERSITE DE GENEVE | 436.275 € |
| Universita Degli Studi DI Verona | 280.275 € |
| Universitair Medisch Centrum Utrecht | 1.373.550 € |
| Universite Grenoble Alpes | 129.275 € |
Quelle: https://cordis.europa.eu/project/id/101034420
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Ares Genetics GmbH - EU-Förderung (6.500.000 €): Vorhersage des Einflusses von monoklonalen Antikörpern und Impfstoffen auf antimikrobielle Resistenzen"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
